Regentis Biomaterials (NYSE American: RGNT) is strategically advancing its GelrinC cartilage repair platform by running parallel clinical and commercial tracks in the US and Europe, respectively. This approach aims to compress the typically long timeline between regulatory approval and commercial revenue for development-stage medical technology companies.
The US clinical program is approaching a pivotal milestone. Regentis has passed 50% enrollment in its Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026. The FDA has approved a single-arm protocol using a historical microfracture control data package that the company owns. The first 40 patients in the study closely match this control group, which could support a Premarket Approval (PMA) submission. The company expects to begin the PMA process by the end of 2027.
In Europe, where GelrinC already holds CE Mark approval, the company is focusing on commercial launch. Surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network. A newly approved manufacturing process is expected to increase yield by approximately 400%, which will be crucial for meeting commercial demand.
GelrinC is a cell-free, off-the-shelf hydrogel implant for focal articular cartilage defects in the knee. Unlike traditional approaches that require harvesting and expanding patient cells, GelrinC is ready to use and can be implanted in a procedure lasting roughly 10 minutes. The hydrogel forms a temporary programmed matrix inside the defect, facilitating cartilage repair.
By advancing these workstreams simultaneously, Regentis aims to reduce the time it takes to bring GelrinC to market and generate revenue. The company's progress in both regions highlights its commitment to addressing the significant unmet need in cartilage repair.
For more information on Regentis Biomaterials and its developments, visit the company's newsroom at https://ibn.fm/RGNT.
